BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21074222)

  • 1. [Fulminating hepatitis for imatinib in a patient with chronic myeloid leukaemia].
    Martínez Pascual C; Valdés Mas M; de la Peña Moral JM; Miras López M
    Med Clin (Barc); 2011 Sep; 137(7):329-30. PubMed ID: 21074222
    [No Abstract]   [Full Text] [Related]  

  • 2. [Survival following liver transplant due to imatinib-induced acute liver failure: a case study].
    García-Valdés M; Miras López M; Garrido Corro B; De La Rubia Nieto A
    Farm Hosp; 2012; 36(1):50-1. PubMed ID: 21514865
    [No Abstract]   [Full Text] [Related]  

  • 3. Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia.
    Kong JH; Yoo SH; Lee KE; Nam SH; Kwon JM; Lee SM; Chang HJ; Choi MY; Cho MS; Mun YC; Nam E; Lee SN; Seong CM
    Acta Haematol; 2007; 118(4):205-8. PubMed ID: 18030002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Severe imatinib-induced hepatotoxicity].
    García Hernández FJ; González León R; Castillo Palma MJ; Sánchez Román J
    Med Clin (Barc); 2012 May; 138(14):638; author reply 638-9. PubMed ID: 22137996
    [No Abstract]   [Full Text] [Related]  

  • 5. [Imatinib mesylate-induced acute cytolytic hepatitis].
    Rocca P; El Jastimi S; Troncy J; Scoazec JY; Boucher A; Vial T; Trépo C; Zoulim F
    Gastroenterol Clin Biol; 2004 Oct; 28(10 Pt 1):918-9. PubMed ID: 15523233
    [No Abstract]   [Full Text] [Related]  

  • 6. Nilotinib post-liver transplantation for acute hepatic failure related to imatinib.
    Perini GF; Santos FP; Funke V; Ruiz J; Neto BH; Hamerschlak N
    Leuk Res; 2009 Dec; 33(12):e234-5. PubMed ID: 19632720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nilotinib in a patient with postnecrotic liver cirrhosis related to imatinib.
    Spataro V
    J Clin Oncol; 2011 Jan; 29(3):e50-2. PubMed ID: 20956624
    [No Abstract]   [Full Text] [Related]  

  • 8. Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate.
    Zonder JA; Schiffer CA
    Curr Hematol Malig Rep; 2006 Sep; 1(3):141-51. PubMed ID: 20425345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histological features of acute hepatitis after imatinib mesylate treatment.
    James C; Trouette H; Marit G; Cony-Makhoul P; Mahon FX
    Leukemia; 2003 May; 17(5):978-9. PubMed ID: 12750713
    [No Abstract]   [Full Text] [Related]  

  • 10. Management of the new patient with CML in chronic phase.
    Marin D
    Curr Hematol Malig Rep; 2013 Mar; 8(1):37-42. PubMed ID: 23381448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.
    Rousselot P; Larghero J; Raffoux E; Calvo F; Tulliez M; Giraudier S; Rybojad M
    Br J Haematol; 2003 Mar; 120(6):1091-2. PubMed ID: 12648085
    [No Abstract]   [Full Text] [Related]  

  • 12. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.
    Arora B; Kumar L; Sharma A; Wadhwa J; Kochupillai V
    Ann Oncol; 2004 Feb; 15(2):358-9. PubMed ID: 14760137
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase.
    Yamazaki R; Okamoto S; Chen CK; Tada S; Saito H; Shibata R; Sakamoto M; Mori T; Ikeda Y
    Leuk Lymphoma; 2006 Jul; 47(7):1427-30. PubMed ID: 16923586
    [No Abstract]   [Full Text] [Related]  

  • 14. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
    Hochhaus A
    Expert Opin Pharmacother; 2007 Dec; 8(18):3257-64. PubMed ID: 18035968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-intolerance to imatinib, dasatinib and nilotinib therapy in a patient with chronic myeloid leukaemia.
    Novitzky-Basso I; Craddock C
    Eur J Haematol; 2011 Jun; 86(6):548-9. PubMed ID: 21477076
    [No Abstract]   [Full Text] [Related]  

  • 16. Imatinib for chronic myeloid leukaemia: a NICE mess.
    Lim D; Muir J
    Lancet; 2001 Dec; 358(9296):1903. PubMed ID: 11741656
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.
    Thierry A; Dreyfus B; Bridoux F; Abou Ayache R; Milin S; Guilhot F; Touchard G
    Nephrol Dial Transplant; 2007 Jun; 22(6):1791-2. PubMed ID: 17308316
    [No Abstract]   [Full Text] [Related]  

  • 18. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.
    Schiffer CA
    N Engl J Med; 2007 Jul; 357(3):258-65. PubMed ID: 17634461
    [No Abstract]   [Full Text] [Related]  

  • 19. A case of chronic myeloid leukemia with eosinophilic interstitial pneumonitis after administration of imatinib mesylate for 11 months.
    Suemori K; Fujiwara H; Watanabe S; Azuma T; Yasukawa M
    Int J Hematol; 2010 Dec; 92(5):777-8. PubMed ID: 21110146
    [No Abstract]   [Full Text] [Related]  

  • 20. [Imatinib-induced toxic hepatitis: description of two cases and review of the literature].
    Fuster F; Medina L; Vallansot R; Granell M; Bruguera M
    Gastroenterol Hepatol; 2007 Nov; 30(9):525-30. PubMed ID: 17980129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.